Galapagos and Janssen part ways following 'therapeutic shift'

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, have been returned to Galapagos. A first-in-human Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Therapy Areas

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.